US Patent 10881680 Method of treating leukemia
Patent 10881680 was granted and assigned to Epizyme on January, 2021 by the United States Patent and Trademark Office.
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+255 characters)
Article
Patent abstract
The present invention relates to methods of treating disorders in which DOT1L-mediated protein methylation plays a part, such as cancer, by administering DOT1L inhibitor compounds and pharmaceutical compositions to subjects in need thereof.
Edits on 13 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 30 Apr, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
108816800
Date of Patent
January 5, 2021
0Patent Application Number
162147830
Date Filed
December 10, 2018
0Official Website
Patent Primary Examiner
Edits on 25 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
108816800
Date of Patent
January 5, 2021
0Patent Application Number
162147830
Date Filed
December 10, 2018
0Official Website
Patent Primary Examiner
Edits on 17 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 9 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10881680 Method of treating leukemia
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10881680
Date of patent
January 5, 2021
Patent application number
16214783
Date Filed
December 10, 2018
Patent primary examiner
Find more entities like US Patent 10881680 Method of treating leukemia
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
